Work

Reversing resistance to cancer immune therapy with antibodies that target GDF-15 protein

Year: 2024

Type: article

Abstract: The protein GDF-15 is a potent immunosuppressor that is overexpressed in many solid tumours and impedes the effects of cancer immunotherapy. In a first-in-human clinical trial, the GDF-15-targeting antibody visugromab reversed GDF-15-mediated resistance to immunotherapy, resulting in deep, long-lasting tumour regressions in some individuals. Resistance to conventional immunotherapy can be broken by a combination of agents.

Source: Nature

DOI: 10.1038/d41586-024-04081-y

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $12,290

OpenAlex ID: W4405268561

FWCI:

Cites: 5

Cited by:

Related to: 10